|
|
|
 |
|||
|
|
|
Trials Standard Risk B-Precursor Acute Lymphoblastic Leukemia (AALL0331) Phase : III Site: Phoenix Status: Open Classification of Acute Lymphoblastic Leukemia (AALL03B1) Phase : Biology Site: Phoenix Status: Open Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies (AALL0433) Phase : III Site: Phoenix Status: Open A Study of Chemoimmunotherapy with Epratuzumab for Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ADVL04P2) Phase : 1/2 Site: Phoenix Status: Open A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens (AALL05B1) Phase : Biology Site: Phoenix Status: Open Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (Initial CR1>/18 months) (AALL02P2) Phase : Pilot Site: Phoenix Status: Open Understanding the Role of Adherence and Ethnic Differences in Survival after Childhood ALL (AALL03N1) Phase : Non-Therapeutic Site: Phoenix Status: Open A Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults (AAML0531) Phase : III Site: Phoenix Status: Open Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years (AAML0431) Phase : III Site: Phoenix Status: Open Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (AALL0434) Phase : III Site: Phoenix Status: Open Intensified PEG-Asparaginase in High Risk Acute Lymphoblastic Leukemia (ALL): A Pilot Study (AALL08P1) Phase : Pilot Site: Phoenix Status: Open A Phase II Study of Dasatinib Therapy in Children and Adolescents with Ph+ Leukemia with Resistance or Intolerance to Imatinib (CA180266) Phase : II Site: Phoenix Status: Open Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Stem Cell Transplantation (SCT) for AML with Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study (AAML05P1) Phase : Pilot Site: Phoenix Status: Open Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib: IND# 73969, NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (AALL0622) Phase : II Site: Phoenix Status: Open Erwinase® Master Treatment Protocol; EMTP (PCH 07-007) Phase : Expanded Access Site: Phoenix Status: Open A Phase II Pilot Study of Bortezomib (PS-341, Velcade, IND #58,443) Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary AML (AAML07P1) Phase : Pilot Site: Phoenix Status: Open Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide (Trisenox, IND#103,331) during Consolidation (AAML0631) Phase : III Site: Phoenix Status: Open Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (AAML08B1) Phase : Biology Site: Phoenix Status: Open A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC (T2008-002) Phase : I Site: Phoenix Status: Open © 2009, Phoenix Children's Hospital.
|
|
Leukemias